This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Introduction. Treatment-Resistant Schizophrenia and Beyond: Current Concepts and Future Prospects.


Published: December 1, 1999

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

The publication of the U.S. Clozaril Multicenter Trial more than a decade ago led to the worldwide use of clozapine (Clozaril, Leponex) for treatment-resistant schizophrenia.1 Despite the subsequent introduction of other atypical antipsychotics, clozapine remains the "gold standard" for treatment of this patient population, with superior efficacy compared with conventional antipsychotics. Indeed, it is the only drug with proven efficacy in treatmentresistant schizophrenia.’ ‹

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 60

Quick Links: Schizophrenia and Schizoaffective Disorders

Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...